Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma

摘要

AIM: This study was designed to evaluate the clinical application of serum total sialic acid (TSA) in the diagnosis of cholangiocarcinoma (CCA). METHODS: Serum TSA was determined by periodate-resorcinol microassay in 69 patients with CCA, 59 patients with hepatocellular carcinoma (HCC), 37 patients with cirrhosis, 61 patients with chronic hepatitis and 50 healthy blood donors. RESULTS: The mean serum TSA concentration in CCA (2.41+-0.70 mmol/L) was significantly higher than those of HCC, cirrhosis, chronic hepatitis and healthy blood donors (1.41+-0.37 mmol/L, 1.13+-0.31 mmol/L, 1.16+-0.26 mmol/ L, and 1.10+-0.14 mmol/L, respectively; P<0.001). Based on ROC curve analysis, a cut-off point of 1.75 mmol/L discriminated between CCA and HCC with a sensitivity, specificity and accuracy of 82.6 %, 83.1 %, and 82.8 %, respectively. CONCLUSION: Based on our results, serum TSA would be a useful marker for the differential diagnosis of CCA from HCC.